IL17A and rheumatoid arthritis: A still significantly large group of patients with psoriasis, PsA or RA do not reach the remission status despite the notable improvement of the clinical outcome following the introduction of biologic agents such as TNFα blockers and those targeting the IL-23/IL-17 axis.